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abstract
Background: It is well known that a significant proportion of hospitalized medical and surgical patients with risk factors 
for deep vein thrombosis (DVT) are not receiving thromboprophylaxis. We designed this study to evaluate the proportion 
of at-risk patients and the proportion of those receiving recommended prophylaxis.
methods: We conducted a multicentric cross-sectional survey that included medical and surgical patients from 43 hos-
pitals throughout Mexico. Patients who were at risk for DVT according to the ACCP 2004 guidelines were included and 
evaluated for thromboprophylaxis. 
results: Overall, 625 patients were at risk: 308 (49%) surgical patients and 317 (51%) medical patients. There were 179 
(58%) surgical patients receiving recommended prophylaxis, whereas medical patients represented 117 (37%) patients.
Conclusions: There is a significant proportion of hospitalized medical and surgical patients at risk for DVT. There is also 
a significant underutilization of recommended thromboprophylaxis among these patients.
Key words: venous thromboembolism, deep vein thrombosis, pulmonary embolism, prophylaxis.
introduction
Venous thromboembolism (VTE) is a common complica-
tion in medical and surgical patients1-8 and is a cause of high 
morbidity and mortality.9-11 Pulmonary embolism (PE) is 
present in >600,000 cases per year in the U.S. and causes or 
is a contributing factor in 50,000-200,000 deaths per year,12 
being reported as the most common cause of preventable 
in-hospital deaths.8,13 In Mexico, Sigler et al. of the Hospital 
General (Centro Medico Nacional, Instituto Mexicano del 
Seguro Social) reported a rate of PE of 15% in 1685 au-
topsies, being the direct cause of death in 28% and indirect 
cause in 62% of cases.14 In another study on 1032 autop-
sies, Sandoval et al. of the Instituto Nacional de Cardiología 
“Ignacio Chávez” reported an incidence of 22%, being the 
third cause of mortality.15
These severe and troublesome figures of hospitalized 
patients with VTE stand out when there is a significant 
gap between national and international guidelines and the 
appropriate use of prophylaxis for this disease. The multi-
national cross-sectional ENDORSE study showed that VTE 
prophylaxis in medical or surgical patients is less than that 
recommended by the guidelines of the American College 
of Chest Physicians (ACCP) in 200416  with greater pro-
phylaxis in the surgical group of patients (58.5%) compared 
to the group of medical patients (39.5%).16
Two meta-analyses also highlighted the underutilization 
of prophylaxis in medical patients. 17,18 An interesting article 
by Howard describes two important data:
Suboptimal use of prophylaxis of medical patients due • 
to inconsistencies and complexity of current guidelines 
in relation to the stratification of the risks of VTE
76% of hospitalized medical patients with one or more • 
risk factors for VTE did not receive appropriate DVT 
prophylaxis in an audit conducted in 2004 at the John 
Radcliffe Hospital in Oxford8 
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Failure of prophylaxis has also been reported in other 
groups of patients. Bratzler et al. in a retrospective study 
of 419 surgical patients 65 years of age or older showed 
that only 38% received prophylaxis. In the group of 250 pa-
tients with very high risk of VTE only 39% received some 
form of prophylaxis, but only 64 of these 97 (66%) received 
appropriate prophylaxis.19 Similar results have been repor-
ted in other studies of patients 65 years or older with other 
risk factors (cancer, previous VTE, heart failure, ischemic 
cerebrovascular disease, infection or sepsis) for VTE due to 
comorbidities and immobilization.20,21
materials and methods
The design was similar to the international ENDORSE re-
gistry:16 national multicentric, observational, cross-sectio-
nal, including the guidelines for DVT prophylaxis of the 
ACCP 2004.22 The primary objectives were as follows: 
Identify the percentage of hospitalized patients at risk • 
for VTE in selected hospitals representative of the 
country
Determine the percentage of hospitalized patients at risk • 
who receive effective types of prophylactic treatment 
for VTE prophylaxis 
Secondary objectives were as follows: 
Define the rate of patients who receive an adequate • 
DVT prophylaxis in medical vs. surgical populations
Define the rate of hospital patients at risk for DVT due • 
to acute disease (i.e., medical and/or surgical)
Analyze the factors to determine adequate prophylaxis• 
Perform the analysis by type of hospital (public and • 
private)
Hospital selection was conducted from a list of representative 
public and private hospitals in Mexico, which met the following 
characteristics: 1) bed capacity ≥50 and 2) with revenues for 
treatment of acute illness or exacerbations of chronic diseases 
and/or who schedule routine major surgeries. Psychiatric, pedia-
tric and rehabilitation hospitals were excluded.
The study, if required, was approved by the Ethics Com-
mittees of each hospital, but no informed consent was sought 
from respondents. In the remaining hospitals there was an 
academic guarantee from the Mexican Academy of Surgery.
Each hospital had a designated principal investigator 
who trained for 1 day on how to complete the required 
forms in the survey. The investigator was also responsible 
for completing the Hospital Recruitment Form, which in-
cluded hospital code (code per hospital) and hospital cha-
racteristics (i.e., number of beds, clinical services available 
and any academic affiliation).
Each principal investigator determined the need for as-
sistance by other physicians and/or nurses who were res-
ponsible for completing two forms: a) Patient Recruitment 
Form (PRF) in each participating hospital that included a 
list of all patients in the eligible services or wards and in-
cluded the patient identification number or reason for study 
exclusion, and b) Case Report Form (CRF) containing the 
data of patients enrolled such as demographic data, admis-
sion diagnosis and diagnoses after admission, risk factors 
for bleeding and risk factors for VTE, length of hospital 
stay, type of surgical procedure on admission or within 14 
days, and type of thromboprophylaxis indicated on the hos-
pital stay and at discharge.
Patient data were taken from the patient’s file and only 
the first 14 days of the hospital stay were taken into consi-
deration.
Eligible patients were medical patients age 40 years or ol-
der admitted for an acute medical illness and surgical patients 
18 years or older undergoing a major surgical procedure un-
der general or epidural anesthesia lasting ≥45 min or having 
suffered a major traumatic event without requiring major sur-
gery, including intracranial injury or admission to a surgical 
service for observation or preoperative evaluation.
Patients selected from the Ob/Gyn hospital were those 
who were reported to have thromboprophylaxis and who 
were admitted with other nonobstetric conditions, i.e., with 
gynecological diseases (cancers, etc.). Excluded were those 
patients admitted to the following services: emergency, psy-
chiatry, pediatrics, palliative care, maternity and obstetrics, 
neonatology, burn units, otolaryngology, dermatology, oph-
thalmology, rehabilitation, admitted for treatment of addic-
tion to alcohol and drugs, admitted for VTE treatment or 
minor surgical treatment, anesthesia lasting <45 min or lack 
of data in the patient’s clinical file.
Statistical Analysis 
Categorical data are presented in numbers and percentages, 
both in the number of patients with risk factors for VTE 
who received thromboprophylaxis and their location by pu-
blic or private hospital.
Population characteristics including demographics, me-
dical history, nature, duration and severity of the disease, 
concomitant diseases and treatment (thromboprophylaxis) 
are presented in complete data sets (average, SD, minimum, 
maximum and median, 95% CI of quantitative variables). 
Data sets and percentages were also performed with 95% 
CI of the population for categorical data. Results were clas-
sified according to hospital.
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The prevalence of risk for VTE according to risk fac-
tors defined by the ACCP (2004) are presented according 
to hospital and divided by patients according to medical or 
surgical category with 95% CI. The analysis was performed 
on populations with a satisfactory level of data. The preva-
lence of thromboprophylaxis according to hospital as well 
as patient distribution according to thromboprophylaxis re-
ceived will be reported.
results 
The survey was conducted in all participating hospitals 
from June 2 to June 16, 2008. Unlike the original ENDOR-
SE study that analyzed the hospitals by beds assigned to the 
services included, our study considered patients admitted 
to these services and not beds assigned by service because 
most of the hospitals in Mexico, especially private hospi-
tals, do not assign a determined number of beds for each 
service where surgical patients share space (floor or area) 
with medical patients.
The number of respondents was 2133 patients in 44 par-
ticipating hospitals, excluding 506 patients who met one or 
more exclusion criteria, leaving 1627 patients for the analy-
sis (Figure 1). Of these 1627 patients, 715 were surgical 
(43.9%) and 777 (47.8%) were males, with a mean age of 
57.15 years (±17 years), mean weight 69.5 kg (±15.4 kg) 
and mean height of 162.2 cm (±9.81 cm). According to the 
guidelines of the ACCP, 625 (38.4%) patients were at risk 
for VTE, 311 (40.0%) patients were males and 317 (44.3%) 
were nonsurgical patients (Table 1).
Other demographic data are presented in Table 2, with 
an average BMI in the overweight category observed. Table 
3 shows the risk factors present for VTE before patient ad-
mission to the hospital. In both groups of patients, obesity 
was the most common risk factor. In the group of medi-
cal patients it was followed by chronic pulmonary disease, 
peripheral vascular disease, long-term immobilization, and 
chronic heart failure. In the surgical group of patients the 
presence of venous insufficiency and long-term immobili-
zation followed obesity.
Among other premorbid conditions prior to hospitaliza-
tion, the following stand out: cardiovascular diseases un-
related to heart failure (18.1%), endocrine and metabolic 
problems (16.7%) and hepatobiliary and gastrointestinal 
problems (10.6%). At the time of admission, gastrointes-
tinal and hepatobiliary problems (18%) nonpulmonary 
infections (17.1%) are predominant. The most frequently 
reported events after hospitalization were pulmonary in-
fection (20%) followed with the same frequency by non-
respiratory infection and noninfectious respiratory disease 
(12.92%). The most frequent risk factors for VTE in both 
groups of patients during hospitalization were the presence 
of central venous catheter (CVC) and complete or limited 
immobilization (Table 4).
In relation to the limitation of pharmacological throm-
boprophylaxis, the use of NSAIDs was present in 40.3% of 
patients, followed by significant renal damage in 20.4%, 
and thrombocytopenia in 14.0% of the patients (Table 5). 
Of the 625 (38.4%) patients at risk for VTE, only 295 
(47.2%) received prophylaxis according to ACCP guide-
lines. In the surgical group at risk for VTE (308 patients, 
Complete population
n = 2133
Population with 
“intent to treat”
n = 2133
Valid population 
for survey
n = 1627
Patients with risk
n = 625
Excluded patients
n = 506
Patients without risk
n = 1002
figure 1. Flow diagram in the selection of patients.
table 1. Total number and percentage of patients at 
risk for VTE
Type of illness
Number/total 
patients %
Medical
  With risk for VTE
  Without risk for VTE
715/1627
317
398
43.9
44.3
55.7
Surgical
  With risk for VTE
  Without risk for VTE
912/1627
308
604
56.1
33.8
66.2
Female
  With risk for VTE
  Without risk for VTE
850/1627
314
536
52.2
36.9
63.1
Male
  With risk for VTE
  Without risk for VTE
777/1627
311
466
47.8
40.0
60.0
VTE, venous thromboembolism.
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table 2. Average BMI of patients at risk for venous thromboembolism
Parameter
Patients
(n) Minimum Maximum Average SD
Age (years)
  Male
  Female
1627
501
574
18.0
18.0
18.0
105.0
94.0
94.0
57.15
54.8
57.3
17.1
17.5
16.1
Weight (kg)*
  Male
  Female
1185
501
574
34.0
35.0
34.0
142.0
142.0
130.0
69.5
74.6
64.6
15.4
14.8
14.1
Length (cm)*
  Male
  Female
1082
501
574
103.0
103.0
134.0
194.0
194.0
188.0
162.2
168.5
156.8
9.81
8.5
7.3
BMI (kg/m2)
  Male
  Female
1075
501
574
12.47 58.44 26.27
26.27
26.32
5.1
 Average body mass index (BMI) was in the range of overweight. 
*Weight and length unavailable in all study patients.
SD, standard deviation. 
table 3. Pre-morbid risk factors for venous thromboembolism present at admission
Previous medical condition Medical illness (317)
 n              %
Surgical illness (308)
n              %
General
n              %
Obesity 114 35.9 179 58.1 293 46.8
Previous VTE   29   9.1   18 5.8   47   7.5
COPD   61 19.2   29 9.4   90 14.4
Thrombophilia     5   1.5     3 0.97     8   1.2
Long-term immobilization   46 14.5   49 15.9   95 15.2
Contraceptive use     2     0.63     8 2.5   10   1.6
Venous insufficiency   60 18.9   66 21.4 126 20.1
Pregnancy     5   1.5   10 3.2   15   2.4
Chronic cardiac failure   42 13.2   27 8.7   69 11.0
HRP     2     0.63 3 (0.97%)     5   0.8
VTE, venous thromboembolism; COPD, chronic obstructive pulmonary disease; HRP, hormone replacement 
therapy.
49.3%) only 179 received thromboprophylaxis (58.1% of 
patients), whereas in the medical group of 317 patients 
(50.7%), 117 (36.9%) received thromboprophylaxis (Fi-
gure 2). Pharmacological prophylaxis in medical patients 
was used in 81/317 patients (25%) and 97/308 (31.5%) 
of surgical patients. Mechanical prophylaxis was used 
in 57 medical patients (18.0%) and 120 surgical patients 
(39.0%). No patient received antiplatelet therapy as VTE 
prophylaxis.
Low molecular weigh heparin (LMWH) was the most 
commonly used pharmacologic prophylaxis in patients 
prior to admission, at admission and during the subsequent 
14 days of hospitalization (Table 6). LMWH enoxaparin 
was the most widely used (98.8%). In relation to mechani-
cal prophylactic methods, graduated compression stockings 
were the most frequently used (>90% of cases).
Of the patients surveyed, 1129 (69.4%) were from public 
hospitals. According to type of patient at risk of VTE and 
type of hospital, 433 (69.2%) were in public hospitals and 
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192 (30.8%) were patients in private hospitals. The frequen-
cy of medical patients was higher in public hospitals and on 
a reciprocal basis was observed with surgical patients.
discussion 
ENDORSE II is a supplement to the International ENDOR-
SE Registry16 and the results are preferentially compared 
with this registry, taking special consideration of the per-
table 4. Risk factors for VTE present prior to admission, at the time of admission and 
in the 14 days following hospital admission 
 Medical illness Surgical illness
 Pre-admission Admission Post-admission Pre-admission Admission Postadmission
n % n % n % n % n % n %
Admitted to ICU 11   4.9 35     9.26 12     9.30 20   8.5 67   14.19 62   17.61
CVC 43 19.2 67 17.7 50 38.7 30 12.8 83 17.5 95 26.9
MV 10   4.4 28   7.4 19 14.7 19   8.1 59 12.5 50 14.2
Inmobilization with bathroom 
privileges
54 24.1 152 40.2 18 13.9 60 25.6 131 27.7 79 22.4
Complete immobilization 56 25.0 85 22.4 19 14.7 77 32.9 131 27.7 63 17.9
Chemotherapy 49 21.8 11     2.91 10   7.7 27 11.5 0   0.0 1   0.2
Heparin-induced 
thrombocytopenia
1     0.45 0   0.0 1     0.78 1     0.43 1     0.21 2   0.5
ICU, intensive care unit; CVC, central venous catheter; MV, mechanical ventilation.
table 5. Number and percentage of conditions 
limiting pharmacological prophylaxis 
in patients at risk for VTE
Condition n (625) %
Renal damage 128 20.4
Intracranial hemorrhage 51     8.16
Thrombocytopenia 88 14.0
Known hemorrhagic condition 25   4.0
Hepatic damage 40   6.4
Hemorrhage at hospital admission 72  11.5
Active GI ulcer 26   4.1
Aspirin 78 12.4
NSAIDs 252 40.3
GI, gastrointestinal; NSAIDs, nonsterioidal antiinflammatory 
drugs.
centages of patients at risk of VTE and the use of thrombo-
prophylaxis in medical and surgical patients.
Our survey population with risk factors (ACCP 
guidelines2004) was comprised of 625 patients (38.4%), 
lower than the percentage of patients at risk from the In-
ternational ENDORSE Registry (52%)16 and the percentage 
found in patients surveyed only in Mexico in the same study 
(57%) (477/838 patients) (Martinez ZR, personal commu-
nication).
Moreover, VTE prophylaxis was low (47.2%), similar to 
the average of the International ENDORSE Registry (50%) 
and that of Mexico as part of it (45%). Results of this cross-
sectional survey confirm data reported in other studies with 
a high incidence of at-risk patient for VTE and low throm-
boprophylaxis.8,16-18 Few studies have shown a higher per-
centage of thromboprophylaxis in medical patients at risk, 
reaching 60%.23
It is noted in the International ENDORSE Registry that 
the possible explanation for this discrepancy could be a 
broader definition of the prophylactic methods for VTE and 
a population of patients in academic centers being surve-
yed. The latter information was not collected in our survey.
Regarding types of patients, the surgical group was more 
protected (58.1%) than the medical group (36.9%). As in 
previous comparisons, these data are similar to that repor-
ted in the international ENDORSE study, with prevention 
in the surgical group of 58.1%, and in the medical group of 
39.6%. 
These data can be related to a greater awareness of the 
problem of VTE in surgical patients who frequently have 
more risk factors (surgery, immobilization, trauma, neo-
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table 6. Number, percentage of illnesses and type of pharmacological prophylaxis 
used in VTE
Pharmacological prophylaxis   Preadmission   Admission
  Postadmission
  (1 or more days)
  n %   n % n %
LMWH 25 64.1 55 93.2 422 90.9
Nonfractionated heparin 3 7.6 3 5.0 34 7.3
Vitamin K antagonists 7 17.9 1 1.6 5 1.0
Fondaparinux 0 0.0 0 0.0 1 0.2
Other anticoagulants 4 10.2 0 0.0 2 0.4
VTE, venous thromboembolism; LMWH, low molecular weight hepain.
figure 2. Number and percentage of the total population at risk for venous thromboembolism (VTE) who received thromboprophylaxis (Gui-
delines of the ACCP, 7th ed.) and distribution according to group of surgical patients and medical patients.
625 patients with risk of VTE (38.4%)
296 patients with prophylaxis (47.2%)Primary objectives
Secondary objectives Surgical Medical
308 with risk of VTE (49.3%)
179 with prophylaxis (58.1%)
317 with risk of VTE (50.7%)
117 with prophylaxis (36.9%)
plasms, etc.).24 Regarding this point, Howard states that 
the discrepancies and contradictions between the various 
current guidelines are an important reason in their lower 
use in the group of medical patients.8 An example of these 
inconsistencies is described by the same author in the SIGN 
guidelines, where aspirin is mentioned as a prophylactic 
VTE agent, which differs from the ACCP guidelines.8,22 Our 
survey reported an invalid use of antiplatelet drug as a pro-
phylactic measure for VTE, more in keeping with the ACCP 
guidelines of 2004 and 2008.22,25 Cohen et al. also mention 
that this difference simply is an assessment of surgical pa-
tients.16 Like the international ENDORSE study, our survey 
used the 2004 ACCP guidelines for defining patients at risk 
and effective thromboprophylaxis, thus avoiding bias in the 
stratification of patients and adequacy of prophylaxis. 
In our survey, obesity was an important risk factor for 
VTE (35.9% in the group of medical patients and 58.1% 
in the surgical group of patients), numbers well above tho-
se reported in international ENDORSE study16 and in con-
junction with the high incidence of obesity in the Mexican 
population. This factor has been implicated as an indepen-
dent risk factor for VTE.5,26 Venous insufficiency and immo-
bilization were the most frequent risk factors present before 
admission and during the hospital stay. Chronic heart failure 
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and chronic lung disease had a lower incidence in relation 
to the international ENDORSE registry.16 All these factors 
have been described extensively in the literature as factors 
that should be considered when deciding to initiate throm-
boprophylactic methods.9,13,19-20,24
Using the same methodology of inquiry as the interna-
tional ENDORSE registry, we found the same limitations. 
It is likely that the survey population does not adequately 
represent the population of medical and surgical patients of 
other hospitals. Our country has a large number of hospitals 
with <50 beds (not included in the survey) where there is 
a high probability of not following any guidelines to stra-
tify patients at risk of VTE and at least receive some form 
of prophylaxis. The population also varies significantly in 
cultural and economic terms and the possibility of not re-
ceiving appropriate pharmacologic thromboprophylaxis is 
high. Due to the cross-sectional design of the survey, we 
were not able to analyze whether thromboprophylaxis was 
continued beyond the day of data collection.
Our results with a high number of at-risk patients for 
VTE and low use of thromboprophylaxis are consistent 
with the suggestion of several authors to recognize this as a 
public health problem. VTE is the most important preventa-
ble complication of increased mortality and its development 
(DVT and/or PE) implies an increase in days of hospitaliza-
tion, cost and mortality.8,27 With the same vision worldwide, 
organizations dedicated to the development of guidelines 
on patient safety and quality of care such as the U.S. Joint 
Commission for Hospital Accreditation (Joint Commission) 
have established guidelines on the monitoring of policies 
on prevention of VTE. This information should ultimately 
lead to a commitment in each hospital to develop strategies 
to implement the rational use of thromboprophylaxis (with 
management guidelines), both mechanical and/or pharma-
cological.28 
In conclusion, as in the international ENDORSE study, 
the frequency of medical and surgical patients at risk for 
VTE is high and its prophylaxis is low. Surgical patients 
received VTE prophylaxis more frequently than medical 
patients with results similar to those observed in the interna-
tional ENDORSE study. These findings highlight the urgent 
need to improve monitoring of this prophylactic measure in 
patients at risk for VTE.
Study Group (ENDORSE II)
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